Median Technologies S.A. (ALMDT.PA) Stock Analysis & Winston Score

Median Technologies is a French medical technology company that builds artificial intelligence software to help doctors detect and analyze diseases — mainly cancer — using medical images like CT scans. Its core product is the iBiopsy platform, which uses AI to examine lung nodules and other tissue patterns without a physical biopsy. The company sells primarily to hospitals, research institutions, and pharmaceutical companies running clinical trials. Median makes money by licensing its software and partnering with drug companies that need imaging analysis tools for their clinical studies. It is based in Sophia Antipolis, France, and operates mainly in Europe and the United States, though it remains a small, pre-profit company still in a growth and development phase. The deeply negative margins reflect heavy spending on research and regulatory approvals, and the key risk is that the company must secure broader clinical adoption and regulatory clearances — particularly in the U.S. — before it can build a sustainable revenue base.